Jasper Therapeutics, Inc. (NASDAQ:JSPRW – Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 6,729 shares, a growth of 94.7% from the April 15th total of 3,456 shares. Based on an average daily volume of 14,318 shares, the short-interest ratio is presently 0.5 days.
Jasper Therapeutics Price Performance
Shares of NASDAQ:JSPRW remained flat at $0.02 on Monday. The stock had a trading volume of 506 shares, compared to its average volume of 20,250. Jasper Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.18. The business has a 50-day moving average of $0.02 and a 200 day moving average of $0.06.
About Jasper Therapeutics
Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.
The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.
Featured Articles
- Five stocks we like better than Jasper Therapeutics
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
